Safety Evaluation of THC-Free Hemp Protein Isolate

The goal of this clinical trial is to evaluate the safety and tolerability of a THC-free hemp protein supplement in healthy adult volunteers aged 18-65 years who do not use cannabis or hemp-derived products. The main questions this study aims to answer are: Does twice-daily consumption of 20 grams of Agoge Hemp Protein Powder for 30 days result in detectable levels of THC-COOH, the primary metabolite of THC, in urine samples? Is the supplement well tolerated, and does it affect common clinical safety markers (e.g., liver and kidney function, inflammatory markers)? This is a single-arm study with no comparison group. All participants will: * Consume 20 grams of the hemp protein supplement twice daily for 30 days * Provide blood and urine samples at baseline and Day 30 * Complete weekly surveys assessing adherence, tolerability, and adverse events

NCT Number	NCT07022275
Lead Sponsor	National University of Natural Medicine
Conditions	Tolerability of Hemp Protein
Enrollment	32 participants
Start Date	2025-03-15
Primary Completion	2026-04-25 (estimated)
Study Completion	2026-04-25 (estimated)
Updated on ClinicalTrials.gov	2026-05-12